Novo Nordisk’s Blockbuster Wegovy Drug Sales Beat Expectations
The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.
Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed ...
Wegovy sales are slaying for Novo Nordisk right now
Sales of Novo Nordisk’s (NVO) blockbuster weight loss drug Wegovy continue to soar, surpassing Wall Street expectations. The ...
NBC Los Angeles21h
Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...
Novo Nordisk expects high demand for its obesity drugs in India, says country head
Popular weight-loss drug Wegovy maker Novo Nordisk expects high demand and acceptance for its anti-obesity drug, when ...
GlobalData on MSN10h
Strong Wegovy revenue growth for Novo Nordisk but shares dip
Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same ...
Investopedia on MSN13h
Novo Nordisk Stock Slips as Sales Grow Less Than Expected
After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
Scientist behind Novo Nordisk's Ozempic, Wegovy started her career developing laundry detergent
Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...
Novo Nordisk, in a mixed-bag earnings report, beat expectations on Wegovy sales but tightened its 2024 outlook
Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its year-end outlook. Wall Street wasn't cheery about that.